Frontiers | LncRNA SNHG7 Regulates Mesenchymal Stem Cell Through the Notch1/Jagged1/Hes-1 Signaling Pathway and Influences Folfirinox Resistance in Pancreatic Cancer
Subtyping for pancreatic cancer precision therapy: Trends in Pharmacological Sciences
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma
Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancr
TAM are decreased following treatment with FOLFIRINOX+PF-04136309... | Download Scientific Diagram
Cells | Free Full-Text | Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial - The ...
Cells | Free Full-Text | Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Therapeutic developments in pancreatic cancer: current and future perspectives | Nature Reviews Gastroenterology & Hepatology
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction - ScienceDirect
Systemic Treatment and Outcomes of Metastatic Pancreatic Cancer
Multi-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro | Scientific Reports
Multi-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma
Frontiers | Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study in: Journal of the National Comprehensive Cancer Network Volume 20 Issue 7 (2022)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Ca
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage | Nature Communications
IJMS | Free Full-Text | Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
Folfirinox for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDA); Clinical Outcomes and Prognostic Factors,
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data - ScienceDirect
Scheme for determining the cumulative relative dose intensity of each... | Download Scientific Diagram
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study | SpringerLink
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial - The Lancet Oncology
